Company / R&D per Share
Cardiff Oncology, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.53
FY2025
5-year range
$0.47 / $0.74
FY2021-FY2025
Trend
-27.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has fluctuated over the past 10 years, ranging from $0.22 in FY2016 to $10.75 in FY2018.
Based on SEC 10-K filings.
0.53 in FY2025 with a 5-year CAGR of -16.5%.
Declined from $0.61 to $0.53 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -6.3%
- 5-Year CAGR
- -16.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 27.8% year-over-year.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.53 | -27.8% |
| FY2024 | $0.74 | +21.2% |
| FY2023 | $0.61 | -6.0% |
| FY2022 | $0.65 | +36.5% |
| FY2021 | $0.47 | -63.8% |
| FY2020 | $1.31 | -55.1% |
| FY2019 | $2.91 | -72.9% |
| FY2018 | $10.75 | +2099.1% |
| FY2017 | $0.49 | +118.1% |
| FY2016 | $0.22 | -60.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026